AGR2 predicts tamoxifen resistance in postmenopausal breast cancer patients
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00209805%3A_____%2F13%3A%230000428" target="_blank" >RIV/00209805:_____/13:#0000428 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.1155/2013/761537" target="_blank" >http://dx.doi.org/10.1155/2013/761537</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1155/2013/761537" target="_blank" >10.1155/2013/761537</a>
Alternative languages
Result language
angličtina
Original language name
AGR2 predicts tamoxifen resistance in postmenopausal breast cancer patients
Original language description
Endocrine resistance is a significant problem in breast cancer treatment. Thus identification and validation of novel resistance determinants is important to improve treatment efficacy and patient outcome. In our work, AGR2 expression was determined by qRT-PCR in Tru-Cut needle biopsies from tamoxifen-treated postmenopausal breast cancer patients. Our results showed inversed association of AGR2 mRNA levels with primary treatment response (P = 0.0011) and progression-free survival (P = 0.0366) in 61 ER-positive breast carcinomas. As shown by our experimental and clinical evaluations, elevated AGR2 expression predicts decreased efficacy of tamoxifen treatment. From this perspective, AGR2 is a potential predictive biomarker enabling selection of an optimal algorithm for adjuvant hormonal therapy in postmenopausal ER-positive breast cancer patients.
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2013
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Disease Markers
ISSN
0278-0240
e-ISSN
—
Volume of the periodical
35
Issue of the periodical within the volume
4
Country of publishing house
US - UNITED STATES
Number of pages
6
Pages from-to
207-212
UT code for WoS article
000324981400001
EID of the result in the Scopus database
—